Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Evandro D. Bezerra, Mary E. Flowers, Lynn E. Onstad, Deborah Chielens, Jerald Radich & Celestia S. Higano. (2019) A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation. Leukemia & Lymphoma 60:11, pages 2754-2761.
Read now
Read now
Catherine Burton, David Marin & Jane Apperley. (2005) Personalized medical treatment strategies for patients with chronic myeloid leukemia. Expert Review of Anticancer Therapy 5:2, pages 343-353.
Read now
Read now
Articles from other publishers (25)
Nirali N. Shah, Michael J. Borowitz, Nancy C. Robey, Christopher J. Gamper, Heather J. Symons, David M. Loeb, Alan S. Wayne & Allen R. Chen. (2014) Feasibility of Treating Post-Transplantation Minimal Residual Disease in Children with Acute Leukemia. Biology of Blood and Marrow Transplantation 20:7, pages 1000-1007.
Crossref
Crossref
Jeffrey R. AndolinaSteven M. Neudorf & Seth J. Corey. (2012) How I treat childhood CML. Blood 119:8, pages 1821-1830.
Crossref
Crossref
Nicola Daniele, Maria Cristina Scerpa, Maurizio Caniglia, Maria Ester Bernardo, Cecilia Rossi, Chiara Ciammetti, Giuseppe Palumbo, Franco Locatelli, Giancarlo Isacchi & Francesco Zinno. (2012) Transplantation in the onco-hematology field: Focus on the manipulation of αβ and γδ T cells. Pathology - Research and Practice 208:2, pages 67-73.
Crossref
Crossref
Robertson D. Davenport & Paul D. Mintz. 2011. Henry's Clinical Diagnosis and Management by Laboratory Methods. Henry's Clinical Diagnosis and Management by Laboratory Methods
731
745
.
Terry J. Fry & Arjan C. Lankester. (2010) Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?. Hematology/Oncology Clinics of North America 24:1, pages 109-127.
Crossref
Crossref
Hon Fong L. Mark, Susana C. Raimondi & Robert Sokolic. 2010. Mechanisms of Oncogenesis. Mechanisms of Oncogenesis
89
113
.
Fatma V. Okur & Malcolm K. Brenner. 2010. Immunotherapy of Cancer. Immunotherapy of Cancer
319
345
.
Koen van Besien, Dan Pollyea & Andrew Artz. 2010. Allogeneic Stem Cell Transplantation. Allogeneic Stem Cell Transplantation
657
666
.
Jo-Anne Vergilio & Adam Bagg. 2009. Molecular Pathology in Clinical Practice: Oncology. Molecular Pathology in Clinical Practice: Oncology
213
226
.
Terry J. Fry & Arjan C. Lankester. (2008) Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?. Pediatric Clinics of North America 55:1, pages 147-167.
Crossref
Crossref
F. Dazzi & C. Fozza. (2007) Disease relapse after haematopoietic stem cell transplantation: Risk factors and treatment. Best Practice & Research Clinical Haematology 20:2, pages 311-327.
Crossref
Crossref
Martha L. Arellano, Amelia Langston, Elliott Winton, Christopher R. Flowers & Edmund K. Waller. (2007) Treatment of Relapsed Acute Leukemia after Allogeneic Transplantation: A Single Center Experience. Biology of Blood and Marrow Transplantation 13:1, pages 116-123.
Crossref
Crossref
Charles Crawley, Jerald Radich & Jane Apperley. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders
115
131
.
Jo-Anne Vergilio & Adam Bagg. 2007. Molecular Pathology in Clinical Practice. Molecular Pathology in Clinical Practice
383
396
.
Irene A.G. Roberts & Inderjeet S. Dokal. 2006. Pediatric Hematology. Pediatric Hematology
384
404
.
Enrica Orsini, Elisabetta Calabrese, Roberta Maggio, Alessia Pasquale, Mauro Nanni, Stefania Trasarti, Agostino Tafuri, Anna Guarini & Robert Foa. (2006) Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation. Leukemia Research 30:7, pages 785-794.
Crossref
Crossref
Rinat Eshel, Oded Vainas, Meirav Shpringer & Elizabeth Naparstek. (2006) Highly Sensitive Patient-Specific Real-Time PCR SNP Assay for Chimerism Monitoring after Allogeneic Stem Cell Transplantation. Laboratory Hematology 12:1, pages 39-46.
Crossref
Crossref
Helmut Borberg. (2006) Quo vadis haemapheresis. Transfusion and Apheresis Science 34:1, pages 51-73.
Crossref
Crossref
Jane F. Apperley. (2006) Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation. Hematology 2006:1, pages 226-232.
Crossref
Crossref
Anton V.M.B. Schattenberg & Harry Dolstra. (2005) Cellular adoptive immunotherapy after allogeneic stem cell transplantation. Current Opinion in Oncology 17:6, pages 617-621.
Crossref
Crossref
U Banning, T Lange, R Krahl, C Mauz-Körholz, J Krutmann, D Niederwieser & D Körholz. (2005) Prognostic value of T-1 cell numbers prior to allogeneic stem cell transplantation in patients with severe graft-versus-host disease. Bone Marrow Transplantation 35:7, pages 691-697.
Crossref
Crossref
Lawrence S. LambJr.Jr. & Richard D. Lopez. (2005) γδ T cells: A new frontier for immunotherapy?. Biology of Blood and Marrow Transplantation 11:3, pages 161-168.
Crossref
Crossref
Kazuyuki Matsuda, Kazuyoshi Yamauchi, Minoru Tozuka, Takefumi Suzuki, Mitsutoshi Sugano, Eiko Hidaka, Kenji Sano & Tsutomu Katsuyama. (2004) Monitoring of Hematopoietic Chimerism by Short Tandem Repeats, and the Effect of CD Selection on Its Sensitivity. Clinical Chemistry 50:12, pages 2411-2414.
Crossref
Crossref
Greg R Angstreich, B Douglas Smith & Richard J Jones. (2004) Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. Current Opinion in Oncology 16:2, pages 95-99.
Crossref
Crossref
. (2003) Current Awareness in Hematological Oncology. Hematological Oncology 21:2, pages 91-98.
Crossref
Crossref